Bone Growth Compositions and Methods

• US 20120276204A1
• Filed: 11/29/2011
• Published: 11/01/2012
• Est. Priority Date: 06/13/2002
• Status: Active Grant

• Current Assignee: Neuropro Technologies Inc.
• Original Assignee: Neuropro Technologies Inc.
• Inventors: Remington, Benjamin J., Bearss, David J., Shahi, Kavian
• Granted Patent: US 9,155,629 B2
• Time in Patent Office: Days
• US Class Current: 424/484
• CPC Class Codes: A61F 2/28 Bones joints A61F2/30
• CPC Class Codes: A61F 2/4405 for apophyseal or facet joints, i.e. between adjacent spinous or transverse processes devices implanted between spinous or transverse processes A61B17/7062
• CPC Class Codes: A61F 2/4455 for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages intervertebral discs A61F2/442
• CPC Class Codes: A61F 2002/2817 Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
• CPC Class Codes: A61F 2002/30224 cylindrical
• CPC Class Codes: A61F 2002/30677 Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
• CPC Class Codes: A61F 2230/0069 cylindrical
• CPC Class Codes: A61F 2310/00359 Bone or bony tissue
• CPC Class Codes: A61F 2310/00365 Proteins; Polypeptides; Degradation products thereof
• CPC Class Codes: A61F 2310/00796 Coating or prosthesis-covering structure made of a phosphorus-containing compound, e.g. hydroxy(l)apatite
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/434 of enzymes
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders

Abstract

The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.

Claims

1. A method for enhancing non-anatomic bone formation in a site, the method comprising the steps of administering an HMG-CoA reductase inhibitor to the site.

2. The method of claim 1 wherein the HMG-CoA reductase inhibitor is lovastatin, or any salt, drug or derivative thereof.

3. The method of claim 1, wherein the HMG-CoA reductase inhibitor is pravastatin, or any salt, drug or derivative thereof.

4. The method of claim 1 wherein the HMG-CoA reductase inhibitor is simvastatin, or any salt, drug or derivative thereof.

5. The method of claim 1 wherein the HMG-CoA reductase inhibitor is atorvastatin, or any salt, drug or derivative thereof.

6. The method of claim 1 wherein the HMG-CoA reductase inhibitor is dalvastatin, or any salt, drug or derivative thereof.

7. The method of claim 1 wherein the HMG-CoA reductase inhibitor is fluindostatin, or any salt, drug or derivative thereof.

8. The method of claim 1 wherein the HMG-CoA reductase inhibitor is cerivastatin, or any salt, drug or derivative thereof.

9. The method of claim 1 wherein the HMG-CoA reductase inhibitor is mevastatin, or any salt, drug or derivative thereof.

10. The method of claim 1 wherein the HMG-CoA reductase inhibitor is velostatin, or any salt, drug or derivative thereof.

11. The method of claim 1 wherein the HMG-CoA reductase inhibitor is administed using a carrier.

12. The method of claim 11 wherein the carrier is a non-compressible carrier.

13. The method of claim 11, wherein the non-compressible carrier is coated with the HMG-CoA reductase inhibitor.

14. The method of claim 11 wherein the carrier is a compressible carrier.

15. The method of claim 14 wherein the compressible carrier is a hydrogel.

16. The method of claim 11 wherein the carrier is an open cell matrix.

17. The method of claim 16 wherein the open cell matrix is formed from collagen fibers.

18. The method of claim 17 wherein the collagen fibers are coated with resorbable hydroxyapatite.

19. The method of claim 18 wherein the hydroxyapatite further comprises calcium.

20. The method of claim 11 wherein the carrier further comprises another compound.

21-63. -63. (canceled)